There were 1,026 press releases posted in the last 24 hours and 427,513 in the last 365 days.

Retrophin to Report Fourth Quarter and Full Year 2015 Financial Results

SAN DIEGO, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2015 financial results on Thursday, February 25, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Conference Call Information

Date: Thursday, February 25, 2016      
Time: 4:30 p.m. ET  
Dial-in numbers: +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)  
Confirmation code: 49757304  
Live webcast: www.retrophin.com in the "Events & Presentations" section of the "Investors" page


A replay of the call will be available 7:30 p.m. ET, February 25, 2016 to 11:59 p.m. ET, March 3, 2016. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 49757304.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with no approved treatment options, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the company’s marketed products, Chenodal®, Cholbam® and Thiola®.

Retrophin.com

Contact:
Chris Cline, CFA 
Director, Investor Relations
646-564-3680
IR@retrophin.com	

Primary Logo